USP Pharmaceutical Analytical Impurities

( (3-[2-(Cyclopent-1-en-1-yl)-2-hydroxy-2-phenylacetoxy]-1,1-dimethylpyrrolidin-1-ium bromide)

(4-Amino-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-4H-1,2,4-triazolium methanesulfonate)

(6,11-Dihydro-11-(piperidin-4-ylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine hydrochloride)

(2-Amino-9-Beta-D-ribofuranosylpurine-6(1H)-one)

(2-[2-(2-Amino-6-chloro-9H-purin-9-yl)ethyl]propane-1,3-diyl diacetate)

(Dimethyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate)

(17-Hydroxypregn-4-ene-3,20-dione)

((R)-2-Phenyl-2-pivalamidoacetic acid)

(9,11Beta-Epoxy-17,21-dihydroxy-16Beta-methyl-9Beta-pregna-1,4-diene-3,20-dione)

(Methyl 2-[2-[4-[(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetate dihydrochloride)

(2-[2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]ethoxy]acetic acid dihydrochloride)

((4S)-2-{[3-(2,6-Dichlorophenyl)-5-methylisoxazole-4-carboxamido]methyl}-5,5-dimethylthiazolidine-4-carboxylic acid)

(1-Hydroxy-naphthalene-2-carboxylic acid)

(4-Amino-N-carbamimidoylbenzenesulfonamide)

(3-Isopropoxy-19-nor-(17alpha)-pregn-3,5-dien-20-yn-17-yl acetate)

(2-{2-[4-(Diphenylmethyl)piperazin-1-yl]ethoxy}acetic acid)

((4S)-2-[Carboxy[[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]amino]methyl]-5,5-dimethylthiazolidine-4-carboxylic acid disodium salt)

((1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2R)-2-methylbutanoate)

(2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]propane-1,3-diyl (2S,2'S)-bis(2-amino-3-methylbutanoate) ditrifluoroacetate)

((R)-1-[N-(3-Hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile)

(9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione)

(N-(4-Chlorophenyl)-2-(2,6-dichlorophenyl)acetamide)